Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Pyridostatin (TFA) | 1472611-44-1 | C33H33F3N8O7 | 5 MG
Pyridostatin (TFA) | 1472611-44-1 | C33H33F3N8O7 | 5 MG
Medchemexpress LLC Ribupatide TFA | 2940971-65-1 | 99.8% | 4907.48 | 1 MG
Ribupatide TFA is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. It is orally active and can also be administered by injection, making it suitable for antidiabetic research.
- Dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist
- Can be studied in antidiabetic research
- Orally active
- Can also be administered by injection
Medchemexpress LLC Veldoreotide TFA | 2126831-23-8 | 99.0% | 1237.33 | 5 MG
Veldoreotide TFA (DG3173) is a somatostatin analogue that binds to and activates somatostatin receptors (SSTR) 2, 4, and 5. It inhibits growth hormone (GH) secretion in adenomas and has potential use as a pain modulating agent.
- Activates somatostatin receptors 2, 4, and 5
- Inhibits growth hormone (GH) secretion in adenomas
- May be used as a pain-modulating agent
- Stimulates SST2, SST4, and SST5 receptors in HEK293 cells co-expressing these receptors with GIRK2 channels
- Inhibits SST4-expressing BON-1 cells at 10 μM for 24 hours
Medchemexpress LLC Cyclo(Arg-Pro) TFA | 74838-83-8 | 98.6% | 367.32 | 5 MG
Cyclo(Arg-Pro) TFA is a chitinase inhibitor that disrupts cell separation and morphological transition of yeast by inhibiting chitinase activity. It prevents cell separation of *Saccharomyces cerevisiae*, leading to the formation of grape-like cell clusters, without inhibiting cell growth. Additionally, it blocks the morphological transition of *Candida albicans* from yeast form to hyphal form, without inhibiting cell growth.
- Disrupts cell separation and morphological transition of yeast
- Prevents cell separation of *Saccharomyces cerevisiae*
- Leads to formation of grape-like cell clusters
- Blocks morphological transition of *Candida albicans* from yeast form to hyphal form
Medchemexpress LLC TP-5801 (TFA) | 99.6% | 641.48 | 100 MG
TP-5801 TFA is an orally active TNK1 (non-receptor tyrosine kinase) inhibitor with an IC50 of 1.40 nM, demonstrating anti-tumor activity. It inhibits TNK1-driven, BCR-ABL-driven, and IL-3-driven Ba/F3 cell growth, and TNK1-dependent L540 cell growth.
- Orally active
- Potent TNK1 inhibitor (IC50=1.40 nM)
- Demonstrates anti-tumor activity
- Inhibits growth of various cell lines (Ba/F3 and L540) relevant to TNK1-driven processes
- Shows efficacy in animal models, prolonging lifespan and inhibiting localized tumor growth without signs of toxicity
Medchemexpress LLC Huwentoxin IV | 526224-73-7 | >98% | 1 MG
Huwentoxin-IV TFA is a potent and selective sodium channel blocker, inhibiting neuronal Nav1.7, Nav1.2, Nav1.3, and Nav1.4 with IC50s of 26, 150, 338, and 400 nM, respectively.
- Potent and selective sodium channel blocker
- Inhibits neuronal Nav1.7, Nav1.2, Nav1.3, and Nav1.4
- IC50s of 26, 150, 338, and 400 nM, respectively
![Medchemexpress LLC 6-Benzothiazolamine, N-[6-[2-[(cyclohexylmethyl)amino]-4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (TFA) | 99.1% | 597.58 | 25 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000438226-Logo.png-250.jpg){kind=logo}
Medchemexpress LLC 6-Benzothiazolamine, N-[6-[2-[(cyclohexylmethyl)amino]-4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (TFA) | 99.1% | 597.58 | 25 MG
AMG 7905 TFA is a hypothermia-inducing transient receptor potential vanilloid type 1 (TRPV1) antagonist. It potentiates TRPV1 channels activation by protons and drives the reflectory inhibition of thermogenesis and tail-skin vasoconstriction, while potently blocking channel activation by capsaicin.
- Potentiates TRPV1 channels activation by protons
- Drives reflectory inhibition of thermogenesis and tail-skin vasoconstriction
- Potently blocks channel activation by capsaicin
Medchemexpress LLC Adrixetinib TFA | C27H25F6N5O7 | 25 MG
Adrixetinib TFA is an Axl/Mer/CSF1R inhibitor. This product is supplied as an off-white to light yellow solid, with a purity of 99.82% as determined by HPLC.
- Axl/Mer/CSF1R inhibitor
- High purity (99.82% by HPLC)
- Off-white to light yellow solid appearance
Medchemexpress LLC Sar441255 TFA | 99.93% | 4866.56 (free base) | 5 MG
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. It displays high potency with balanced activation of all three target receptors and shows positive acute glucoregulatory effects in diabetic obese monkeys. This product is for research use only.
- Potent unimolecular peptide
- GLP-1/GIP/GCG receptor triagonist
- Displays high potency
- Balanced activation of target receptors
- Shows positive acute glucoregulatory effects
- For research use only
Medchemexpress LLC Wrwyar-NH2 TFA | 936.07 | 1 MG
Wrwyar-NH2 (TFA) is a control peptide.
- Control peptide for wrwycr-NH2
- Targets DNA/RNA synthesis
- Involved in the cell cycle/DNA damage pathway
Medchemexpress LLC BIBP3226 TFA | 1068148-47-9 | 99.3% | 587.59 | 5 MG
BIBP3226 TFA is a potent and selective neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor antagonist, with Ki values of 1.1, 79, and 108 nM for rNPY Y1, hNPFF2, and rNPFF, respectively. It has been observed to display an anxiogenic-like effect.
- Potent and selective neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor antagonist.
- Ki values of 1.1 nM for rNPY Y1, 79 nM for hNPFF2, and 108 nM for rNPFF.
- Induces an anxiogenic-like effect at higher doses in vivo.
- Available in 5 mg quantity.
Medchemexpress LLC ATX-II TFA | 99.7% | 4934.62 | 500 UG
ATX-II TFA is a selective sodium channel modulator toxin that enhances late sodium current, prevents full sodium channel inactivation, and generates persistent current fractions. It has a pro-arrhythmic effect, slowing intrinsic heart rate and prolonging QT interval. This compound is suitable for research on atrial fibrillation, long QT syndrome, and long QT3 syndrome.